Next Biotech

Learn More about Next Investors - Experts in Biotech Stocks

The CPH Share Price Seems to Have Stabilised – What’s Next?

Next Investors Jan 19, 2021

Today Creso Pharma (ASX: CPH) reported new and follow up Purchase Orders for its animal health medicinal cannabis products totalling over A$345,000.

What’s Happening to the CPH Share Price?

Next Investors Dec 02, 2020

Over recent days, Creso Pharma (ASX: CPH) appears to have gained some significant momentum. Momentum includes three new purchase orders for Creso Pharma’s anibidiol® line of animal health products were signed today, to a value of $A$414,000.

Short Term Trade Update: What’s Happening to the CPH Share Price?

Next Investors Dec 02, 2020

We put out a short note on Creso Pharma (ASX: CPH) to some of you that might have previously invested in the stock and not had a positive experience. After a couple of false starts, our plan is to ride this momentum over the coming weeks and hopefully recoup some of our previous losses.

Canopy Growth Founder Joins a Refreshed, Re-Set and Re-Funded CPH

Next Investors Archived Oct 13, 2020

While Creso Pharma (ASX: CPH) continues to sign purchase orders and has appointed Bruce Linton as an advisor, it is a highly speculative investment, and our intent is to hold for the coming months through to Christmas to see how the company’s strategy plays out.

We are Rolling the Dice on this One…

Next Investors Oct 13, 2020

Long term Creso Pharma (ASX: CPH) shareholders have had a rough ride in the last 12 months. Last week the $20M capped CPH raised circa A$9M at $0.0291 per share, finally extinguishing the company’s debt and ridding the company of major con note holders that were hampering any share price appreciation.

$2.6M Capped eSense-Lab Signs US$600k Revenue Deal

Next Investors Archived Jun 19, 2020

Backed by a new leadership team, ASX-listed biotech junior, eSense-Lab (ASX:ESE) is implementing a new business model that sees it enter joint venture (JV) agreements to quickly reach multiple revenue-generating markets.

OSL’s Pancreatic Cancer Treatment Approved for Sale in Europe

Next Investors Archived May 05, 2020

OncoSil Medical (ASX:OSL) has received CE Mark approval to market and sell its breakthrough implantable radiotherapy treatment for pancreatic cancer in the EU and UK.

Creso’s New Immunity Boosting CBD Hemp Teas Set for Release

Next Investors Archived Mar 24, 2020

Creso Pharma Limited (ASX: CPH) is expanding its available product line with the release of a hemp tea in Q3 2020.

CPH Secures Two Execs from the World’s Largest Cannabis Company

Next Investors Archived Mar 11, 2020

ASX Junior Creso Pharma (ASX: CPH) has appointed two former Canopy executives to the senior management team of its wholly-owned Mernova Medical Inc. in Nova Scotia, Canada.

Scandinavian Sales Agreement Expands Creso Pharma’s European Footprint

Next Investors Archived Mar 04, 2020

Creso Pharma Limited (ASX:CPH, FRA:1X8) has signed a commercial term sheet agreement with Farmagon, Oslo, Norway to enter the Scandinavia market with Creso products.

Can This ASX Junior Surge Through the Pain Barrier?

Next Investors Archived Mar 02, 2020

Biotech company Regeneus (ASX:RGS) is a regenerative medicine company, and the therapy is a novel stem cell therapy.

Creso on a Roll: New Hemp Plant Product for Equines and Large Animals Set for Release

Next Investors Archived Feb 11, 2020

Creso Pharma (ASX:CPH) today announced the successful development of anibidiol®EQUI, a flavoured micromilled hemp plant product for equines and large animals.

CPH Set to Expand cannaQIX® Product Line After Major Technological Breakthrough

Next Investors Archived Feb 06, 2020

Hot on the heels of major developments in human and animal health, Creso Pharma (ASX:CPH) has achieved another key milestone: a technological breakthrough that will expand its cannaQIX® human health product line,

ASX MedTech Junior Displays Promise for Pancreatic Cancer Patients

Next Investors Archived Jan 30, 2020

OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.

CPH’s cannaQIX® Products Have Now Exceeded the 2.5 million Lozenges Sold Milestone

Next Investors Archived Jan 28, 2020

Creso Pharma (ASX:CPH, FRA:1X8) has announced its second major milestone for the year. Today is has informed the market that its flagship cannaQIX® line surpassed the milestone of 100,000 packs sold. The 100,000 pack milestone corresponds to over 2.5 million cannaQIX® lozenges sold since the product’s launch in April 2018.

< prev Page 2 of 7 next >